DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives $12.33 Consensus PT from Analysts

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) has been assigned a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $12.3333.

Several research analysts have recently issued reports on DMAC shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Monday, April 20th. Lake Street Capital reaffirmed a “buy” rating on shares of DiaMedica Therapeutics in a research note on Monday, January 5th.

Institutional Trading of DiaMedica Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Cooperman Leon G raised its holdings in shares of DiaMedica Therapeutics by 98.2% in the third quarter. Cooperman Leon G now owns 3,269,761 shares of the company’s stock valued at $22,463,000 after purchasing an additional 1,619,761 shares during the last quarter. Millennium Management LLC acquired a new stake in shares of DiaMedica Therapeutics in the third quarter valued at approximately $8,157,000. Geode Capital Management LLC raised its holdings in shares of DiaMedica Therapeutics by 99.6% in the second quarter. Geode Capital Management LLC now owns 630,148 shares of the company’s stock valued at $2,458,000 after purchasing an additional 314,407 shares during the last quarter. Paragon Associates & Paragon Associates II Joint Venture raised its holdings in shares of DiaMedica Therapeutics by 34.6% in the third quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 875,000 shares of the company’s stock valued at $6,011,000 after purchasing an additional 225,000 shares during the last quarter. Finally, Royal Bank of Canada raised its holdings in shares of DiaMedica Therapeutics by 46,879.1% in the first quarter. Royal Bank of Canada now owns 155,031 shares of the company’s stock valued at $588,000 after purchasing an additional 154,701 shares during the last quarter. 10.12% of the stock is currently owned by institutional investors and hedge funds.

DiaMedica Therapeutics Trading Up 1.8%

Shares of NASDAQ DMAC opened at $6.33 on Thursday. The firm has a market capitalization of $341.06 million, a PE ratio of -9.04 and a beta of 1.16. DiaMedica Therapeutics has a 1 year low of $3.47 and a 1 year high of $10.42. The firm’s 50-day moving average is $7.20 and its 200-day moving average is $7.59.

DiaMedica Therapeutics (NASDAQ:DMAC) last issued its earnings results on Monday, March 30th. The company reported ($0.17) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.17). The business had revenue of ($0.03) million during the quarter, compared to the consensus estimate of $13.50 million. As a group, equities research analysts anticipate that DiaMedica Therapeutics will post -0.84 earnings per share for the current fiscal year.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.